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This study evaluated the prophylactic effect of Kadukkai maathirai in D-galactosamine (D-gal) induced hepatotoxicity in 
rats. D-galactosamine (D-gal) 400 mg/kg intraperitoneally was used to induce liver damage in rats. To assess the 
hepatoprotective effect of KM, three different doses of KM (36, 72 and 144 mg/kg body weight) were used. The 
hepatoprotective effect of KM was compared with standard drug silymarin (50 mg/kg). The biochemical parameters such as 
AST, ALT, ALP and total bilirubin were estimated. The livers were dissected out to look for histological changes. KM 144 
mg/kg and silymarin showed a significant decrease in AST, ALP and total bilirubin. Both KM and silymarin significantly 
prevented decrease in liver weight. In KM treated groups, the liver did not show necrosis of hepatocytes, and apoptotic 
bodies with mild to moderate inflammatory infiltrate in the lobules and portal tracts. Hence, the results of this study 
confirms the hepatoprotective effect KM in rats.  
Keywords: D-galactosamine, Hepatoprotective, Kadukkai maathirai 
IPC Code: Int. Cl.20: A61K 31/7008, A61P 1/16 
Fulminant hepatitis can be caused by various factors 
including viruses, alcohol and chemicals.This disease 
is associated with a high mortality rate as there 
are no effective prophylaxis or treatment. Liver 
transplantation is the only option in case of fulminant 
hepatitis which is very expensive. Hence newer agents 
need to be developed to treat various liver ailments. 
Extensive research is ongoing around the world to 
understand the pathogenesis of fulminant hepatitis. 
Different animal models are being used to test new 
chemical entities and herbal drugs.One of the models 
commonly used to mimic fulminant hepatitis in rats is 
D-galactosamine (D-gal) induced acute liver injury1.
Hepatic injury by D-galactosamine (D-gal)
resembles human viral hepatitis in its morphological 
and functional features2. The intermediary toxic 
metabolites (UDP-galactosamine and UDP-
glucosamine) of D-gal trap uracil nucleotides 
required for the biosynthesis of nucleic acids and 
proteins3. Subsequently, necrosis of hepatocytes 
occurs. Galactosamine induces activated mast cells to 
release histamine leading to increase in the 
permeability of the gut. Damage by D-galactosamine 
is also due to release of tumor necrosis factor-alpha 
(TNF-α) from Kupffer cells which causes cell death 
by oxidative stress and by triggering inflammation4-6. 
Administration of galactosamine causes inhibition of 
the synthesis of macromolecules in hepatocytes, and 
an increase in the sensitivity to TNF-α-mediated 
events7. 
Many Indian traditional medicines have been used 
in the treatment of liver disease, and there are plenty 
of reports demonstrating hepatoprotective effects of 
various herbs8. Among the traditional Indian 
medicines, the Siddha system of medicine is practiced 
mainly in South Indian states and other South East 
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Asian countries. Kadukkai maathirai (KM), one of the 
polyherbal Siddha preparation is often used to prevent 
and treat liver diseases9,10. 
KM consists of four herbs namely Terminalia 
chebula (Retz.), Piper nigrum (Linn.), Ecliptaalba 
(Linn.), Citrus limon (Linn.), and ferrous sulfate11. 
Each herb contained in KM has been proved to 
exhibit hepatoprotective effect individually against 
different hepatotoxin induced liver disease animal 
models like -isoniazid, rifampicin, and pyrazinamide-
induced liver toxicity; carbon tetrachloride as well as 
thioacetamide-induced liver toxicity. Studies with 
KM alone has been shown to have hepatoprotective 
effect in CCl4-as well as alcohol induced liver toxicity 
in rats12-18. 
The current experiment was undertaken to 
investigate whether Kaddukai maathirai could protect 
against D-galactosamine induced hepatotoxicity. 
 
Material and Methods 
Animals and reagents 
Adult female Sprague Dawley rats weighing about 
150-200 g were used in this study. They were housed 
individually in polypropylene cages at 27 ± 3°C, 
humidity of 60 ± 10%- and 12-hours’ light /dark 
cycle. The study was in accordance with standards 
laid down by Committee for the Purpose of Control 
and Supervision of Experiments on Animals 
(CPCSEA) guidelines following clearance from  
the Institutional Animal Ethics Committee, Manipal. 
(IAEC/KMC/19/2016 dated 16.03.2016). 
D-galactosamine was procured from TCI, 
chemicals industry, Co.Ltd, Tokyo, Japan. All other 
chemicals were obtained from SPINREACT 
chemicals, Spain. Silymarin (standard drug) was 
procured from a local pharmacy. Kadukkai maathirai 
was procured from SKM Siddha and Ayurveda 
Company (India) Ltd, Saminathapuram, 
Modakkurichi, Erode District- 638 104, Tamilnadu, a 
GMP certified company.  
 
Experiment design 
Nine groups with six rats in each was taken for the 
study. D-galactosamine was used to induce liver 
damage. Group I received the vehicle (2% gum 
acacia) and served as control. Groups II, III, IV test 
drug control, received KM 36, 72,144 mg/kg, 
respectively. Group V was kept as toxic (D-gal) 
control and received 2% gum acacia. Groups VI, VII, 
VIII received Kadukkai maathirai (36 mg/kg, 72 
mg/kg and 144 mg/kg, respectively) along with D-gal. 
Group IX received standard drug silymarin (50 
mg/kg) with D-gal. Drugs, other than D-gal, were 
given by oral gavage upto day seven. On day eight,  
D-galactosamine 400 mg/kg was injected 
intraperitoneally in rats of groups V, VI, VII, VIII, 
IX. On the 9th day, body weight was measured, and 
blood was collected by retro-orbital puncture and the 
serum was separated in sterile centrifuge tubes. The 
following serum enzymes were analyzed in serum 
using commercial assay kits obtained from  
Agappe Diagnostics Ltd: aspartate amino transferase 
(AST), alanine amino transferase (ALT), alkaline 
phosphatase (ALP) and total bilirubin. The estimation 
of biochemical parameters was done by standard 
procedures using kits. Rats were sacrificed by  
high dose pentobarbitone, and the liver was  
weighed and fixed in 10% formalin solution for 




The statistical program SPSS 16.0 was used. Data 
were expressed as mean and standard deviation. One-
way ANOVA followed by post hoc Tukey’s test was 
used. Statistical significance was set at p<0.05. 
 
Results 
Biochemical estimation in serum 
Administration of D-galactosamine showed a 
significant (p<0.05) rise in serum AST and ALT, 
ALP, total bilirubin levels than normal control. 
Prophylaxis with KM at 36, 72, 144 mg/kg 
significantly (p<0.05) prevented D-galactosamine 
induced rise in AST and ALT, ALP, total bilirubin 
levels versus those who were administered D-
galactosamine alone (Table 1). Serum ALT level was 
significantly (p<0.05) lower in rats treated with 
silymarin than the group which received KM-144 
mg/kg (p<0.05). Alteration in weight of rats was not 
significant between groups. The weight of the liver in 
D-galactosamine group was significantly reduced 
whereas three different doses KM at 36, 72, 144 
mg/kg and silymarin significantly prevented decrease 
in weight of liver when given prophylactically.  
 
Histopathology 
Histopathological findings of the liver sections of 
normal and test drug treated groups are shown in 
Figure 1. 
Figures 1a-100x, 1b-400x show the liver section of 
group I (normal) rats where hepatic parenchyma with  










Fig. 2 — (a) Photomicrograph of liver tissue of group II (KM in  
36 mg/ kg body weight) showing normal hepatic parenchyma  
with hepatic lobules and occasional cytoplasmic vacuolation;  
low power view (10x) , H&E stain; &( b) - Photomicrograph of 
liver tissue of group II (KM in 36 mg/ kg body weight) showing 
normal hepatic parenchyma with hepatic lobules and occasional 
cytoplasmic vacuolation ; high power view (40x) , H&E stain 
 
normal lobular architecture and cell structure.  
Figures 2a, 2b; 3a, 3b; 4a, 4b- 10× and 40×  
show liver tissue of groups II, III, IV (KM in 36, 72, 
144 mg/ kg body weight) where normal hepatic 
parenchyma with hepatic lobules and occasional 
cytoplasmic vacuolation. Figures 5a, 5b-10×, 40× 
show group V (D-galactosamine) where there were 
extremely pronounced focal necrosis of hepatocytes, 
occasional apoptotic bodies, and also showed  
partially effaced architecture with small clusters of 
lymphocytes within the lobules and portal tracts.  




Fig. 3 — (a) 10x Photomicrograph of liver tissue of group III (KM in 
72 mg/ kg body weight) showing normal hepatic parenchyma with 
hepatic lobules and occasional cytoplasmic vacuolation; low power 
view (10x), H&E stain; & (b) Photomicrograph of liver tissue of 
group III (KM in 72 mg/ kg body weight) showing normal hepatic 
parenchyma with hepatic lobules and occasional cytoplasmic 




Fig. 4 — (a) Photomicrograph of liver tissue of group IV (KM in 
144 mg/ kg body weight) sowing normal hepatic parenchyma  
with hepatic lobules and occasional cytoplasmic vacuolation;  
low power view (10x), H&E stain; & (b) Photomicrograph  
of liver tissue of group IV (KM in 144 mg/ kg body weight) 
showing normal hepatic parenchyma with hepatic lobules  
and occasional cytoplasmic vacuolation; high power view  
(40x), H&E stain 
 
with D-gal) there was better structural appearance of 
the liver without necrosis of hepatocytes, 
andapoptotic bodies with mild to moderate 
inflammatory infiltrate in the lobules and portal tracts 
(Fig. 6a-10×, 6b-40×; 7a-10×, 7b-40×; 8a-10×, 8b-
40×) as compared to group IX (Fig 9a-10×,  
9b-40×). 
 
Table 1 — Effect of Kadukkai maathirai on liver enzymes and bilirubin in D-galactosamine induced liver damage in Sprague Dawley rats 
Group AST(units/L) ALT(units/L) ALP(units/L) Total bilirubin (μmol/L) 
Group I (Normal control) 148.40 ± 7.7 76.20 ± 4.7 334.20 ±95.1 0.24 ± 0.04 
Group II (KM 36 mg/kg) 165.00±16.2 102.00±4.4 287.00±82.3 0.26 ± 0.07 
Group III (KM 72 mg/kg) 192.00±18.2 115.40±12.1 310.00±33.2 0.27±0.08 
Group IV (KM 144 mg/kg) 189.00 ± 33.1 94.00 ± 37.8 269.60 ± 60.0 0.24 ± 0.05 
Group V (D-galactosamine control) 878.60±56.4* 1061.00±119.7* 633.20±113.6* 0.40±0.07* 
Group VI (KM 36 mg/kg+ D-gal) 328.40±68.8** 415.40±51.4** 350.20±26.9** 0.26±0.05** 
Group VII (KM 72 mg/kg+ D-gal) 264.80±45.13** 233.40±68.4**,$ 370.00 ± 77.8** 0.24±0.05** 
Group VIII (KM 144 mg/kg+ D-gal) 173.20±45.0**,$ 348.60±95.3** 284.60±68.5** 0.24 ± 0.05** 
Group IX(Silymarin+D-gal)  194.40 ± 34.7**,$ 201.60 ± 33.7**,$,£ 344.80 ± 77.7** 0.26 ± 0.05** 
*P< 0.05 versus control; **P< 0.05 versus D-galactosamine;  
$P< 0.05 versus group VI;£ P< 0.05 versus group VIII;  






Fig. 5 — (a) Liver tissue of group V(D-galactosamine) showed 
extremely pronounced focal necrosis of hepatocytes, occasional 
apoptotic bodies, and also showed partially effaced architecture 
with small clusters of lymphocytes within the lobules and portal 
tracts; low power view (10x) , H&E stain; & (b) Photomicrograph 
of liver tissue of group V(D-galactosamine) showed extremely 
pronounced focal necrosis of hepatocytes, occasional apoptotic 
bodies, and also showed partially effaced architecture with small 
clusters of lymphocytes within the lobules and portal tracts ; high 




Fig. 6 — (a) Photomicrograph of liver tissue showing of group 
VI(KM 36 mg/kg along with D-gal ) better structural appearance 
of the liver without necrosis of hepatocytes, and apoptotic bodies 
with mild to moderate inflammatory infiltrate in the lobules and 
portal tracts; low power view (10x), H&E stain; & (b) 
Photomicrograph of liver tissue showing of group VI(KM 36 
mg/kg along with D-gal) better structural appearance of the liver 
without necrosis of hepatocytes, and apoptotic bodies with mild to 
moderate inflammatory infiltrate in the lobules and portal tracts; 




Fig. — 7 (a) Photomicrograph of liver tissue showing of group 
VII(KM 72 mg/kg along with D-gal )better structural appearance 
of the liver without necrosis of hepatocytes, and apoptotic bodies 
with mild to moderate inflammatory infiltrate in the lobules  
and portal tracts; low power view (10x), H&E stain; & (b) 
Photomicrograph of liver tissue showing of group VII(KM 72 
mg/kg along with D-gal )better structural appearance of the liver 
without necrosis of hepatocytes, and apoptotic bodies with mild to 
moderate inflammatory infiltrate in the lobules and portal tracts ; 
high power view (40x) , H&E stain 
 
 
Fig. 8 — (a) Photomicrograph of liver tissue showing of group 
VIII(KM 144 mg/kg along with D-gal )better structural 
appearance of the liver without necrosis of hepatocytes, and 
apoptotic bodies with mild to moderate inflammatory infiltrate in 
the lobules and portal tracts; low power view (10x), H&E stain; & 
(b) Photomicrograph of liver tissue showing of group VIII(KM 
144 mg/kg along with D-gal )better structural appearance of the 
liver without necrosis of hepatocytes, and apoptotic bodies with 
mild to moderate inflammatory infiltrate in the lobules and portal 




Fig. 9 — (a) Photomicrograph of liver tissue showing of group 
IX(Silymarin along with D-gal ) ; low power view (10x), H&E 
stain; & (b) Liver tissue showing of group IX(Silymarin along 
with D-gal ); high power view (40x), H&E stain 
 
Discussion 
D-galactosamine-induced liver injury model is 
commonly used to screen the hepatoprotective effects 
of new chemical entities and also various herbal  
drugs. The changes seen in liver pathology with  
D-galactosamine induced liver damage resembles 
acute viral hepatitis in human beings19,20. Hence,  
this model was chosen in the current study.  
D-galactosamine makes the liver more susceptible to 
oxidative stress as it alters antioxidant status20. 
Various studies in the past have shown that  
D-galactosamine causes a drastic rise in AST, ALT 
and ALP.D-galactosamine causes fulminant hepatitis 
by blocking hepatic protein synthesis, and this could 
be attributed to liver weight loss observed in this  
study21. D-galactosamine-induced liver injury is 
associated with the exhaustion of uracil nucleotides 
leading to inhibition of synthesis of RNA and protein 
which causes necrosis of liver cells22. Administration 
of D-galactosamine in a dose of 400 mg/kg body 
weight i.p. produced extensive liver damage within  
24 hours. As a result, the typical architecture of the 




liver changed to partially affected architecture with 
small clusters of lymphocytes within the lobules and 
portal tracts, focal necrosis of hepatocytes along with 
occasional apoptotic bodies. Subsequently, hepatic 
enzymes seeped into the plasmawhichresulted in a 
significant (p<0.05) rise in serum levels of AST, ALT 
and ALP in D - gal treated rats. 
Silymarin was used as a standard hepatoprotective 
compound in this study as it is known to protect the 
plasma membrane of liver cells23. Silymairn acts by 
reduction of free radicals. It also hinders the entry of 
toxic substances into the liver cells. Also, it promotes 
protein synthesis24. 
In the present study, KM at 36, 72, 144 mg/kg 
significantly (p<0.05) prevented the D-galactosamine 
induced rise in AST and ALT levels. This was 
comparable with standard drug silymarin (Table 2). 
KM drug alone (36, 72, 144 mg/kg) showed a slight 
elevation in liver enzymes without any structural 
damage. This elevation might be because of presence 
of certain minerals or metals in KM as it is a 
polyherbal preparation. The absence of structural 
damage was confirmed by histopathological findings. 
In this study we have not evaluated whether it is self-
limiting or spontaneously reversible. However, in 
future studies this can be evaluated. 
Clinically, AST, ALT, ALP and bilirubin levels are 
elevated in acute hepatitis, and their levels return to 
normal when the healing process starts23. KM consists 
of herbs such as T. chebula, P. nigrum, E. alba, and 
C. limon11. C limon has antioxidants such as Vitamin 
C and flavonoids which target the free radicals25.  
P. nigrum exerts antioxidant effect which could be 
mediated by flavonoids and phenolic constituents. It 
has been shown to inhibit lipid peroxidation, and 
generation of superoxide free radicals26,27. Gallic acid 
and chebulic acid are essential constituents of  
T. chebula. Gallic acid has antioxidant and  
anti-inflammatory properties. Chebulic acid is  
known to be an antioxidant and hepatoprotective 
agent28-31. Coumestans, present in E. alba,  
has been shown to exert a protective effect in liver 
disorders and stimulate liver cell regeneration. KM 
treatment showed significant restoration of the  
altered liver enzymes and bilirubin levels towards  
normal in D-galactosamine intoxicated rats. The 
hepatoprotective effect of KM at the dose of 144 
mg/kg and the standard drug silymarin were 
comparable which was further confirmed by 
histopathological findings.  
 
Conclusions 
The Siddha preparation, Kadukkai maathirai 
exhibited hepatoprotective activity in D-
galactosamine induced liver damage in rats. Hence, 
this study could be a piece of scientific evidence for 
traditional medicine practitioners. The 
hepatoprotective effect exhibited by KM could be 
attributed to its anti-inflammatory and antioxidant 
properties reported earlier.  
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